Nontuberculous Mycobacteria in Cystic Fibrosis

Skolnik, Kate; Kirkpatrick, Gordon; Quon, Bradley S.

doi:10.1007/s40506-016-0092-6

Cited by 68 publications

(57 citation statements)

References 84 publications

(198 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over past decades increasing rates of human disease secondary to NTMs have been reported [112,113,114]. NTMs could affect multiple organs, but pulmonary disease is the most common reason for clinical symptoms as a result of NTM inhalation.…”

Section: Non-tuberculous Mycobacteriamentioning

confidence: 99%

Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

Maselli

Keyt

Restrepo

2017

IJMS

View full text Add to dashboard Cite

The management of patients with chronic respiratory diseases affected by difficult to treat infections has become a challenge in clinical practice. Conditions such as cystic fibrosis (CF) and non-CF bronchiectasis require extensive treatment strategies to deal with multidrug resistant pathogens that include Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Burkholderia species and non-tuberculous Mycobacteria (NTM). These challenges prompted scientists to deliver antimicrobial agents through the pulmonary system by using inhaled, aerosolized or nebulized antibiotics. Subsequent research advances focused on the development of antibiotic agents able to achieve high tissue concentrations capable of reducing the bacterial load of difficult-to-treat organisms in hosts with chronic respiratory conditions. In this review, we focus on the evidence regarding the use of antibiotic therapies administered through the respiratory system via inhalation, nebulization or aerosolization, specifically in patients with chronic respiratory diseases that include CF, non-CF bronchiectasis and NTM. However, further research is required to address the potential benefits, mechanisms of action and applications of inhaled antibiotics for the management of difficult-to-treat infections in patients with chronic respiratory diseases.

show abstract

Section: Non-tuberculous Mycobacteriamentioning

confidence: 99%

Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

Maselli

Keyt

Restrepo

2017

IJMS

View full text Add to dashboard Cite

show abstract

“…A further major risk factor is CF, an autosomal recessive systemic disease that involves the respiratory tract among other organs [12]. Due to the highly viscous airway secretions, CF patients have impaired mucociliary clearance, predisposing them to bacterial infections.…”

Section: Pathogenesis and Risk Factors Of Mycobacterial Diseasementioning

confidence: 99%

Pulmonary disease by non-tuberculous mycobacteria – clinical management, unmet needs and future perspectives

Larsson

Polverino²,

Hoefsloot

et al. 2017

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

The number of patients with pulmonary disease caused by non-tuberculous mycobacteria (NTM) is increasing globally. Poor resistance against infections, for example, due to pre-existing lung diseases, immune deficiency and immune-modulating treatment, predisposes the population to developing pulmonary NTM disease. The incidence of pre-existing lung diseases such as chronic obstructive pulmonary disease and bronchiectasis has also increased. NTM disease diagnosis is often delayed due to non-specific symptoms. The therapeutic arsenal is limited and adherence to treatment guidelines is often low since the treatment regimens are complex, lengthy and side effects are common. Thus, current disease management is far from satisfactory and needs to be improved. Areas covered: This review provides an overview of the current knowledge of NTM infections and includes pathogenesis, disease patterns, epidemiology, disease management, unmet needs and future perspectives. Expert commentary: NTM disease is becoming more prevalent, in part with our increased awareness and improved diagnostic methods. However, our understanding of the disease pathogenesis is limited and treatment decisions are challenging, with difficult to employ drug regimens. Optimal management requires collaboration between healthcare providers, patients and expert centers.

show abstract

“…There is also emerging evidence to suggest transmission of M. abscessus complex between individuals with CF [11,12]. NTM PD is challenging to treat requiring multiple antibiotic regimes for a prolonged period of at least 12 months [13,14]. The antibiotics used are frequently associated with adverse effects and represent a significant treatment burden for patients.…”

Section: Introductionmentioning

confidence: 99%

NonTuberculous Mycobacteria Infection and Lung Transplantation in Cystic Fibrosis: A Worldwide Survey of Clinical Practice

Brodlie

Tissot

Thomas

et al. 2017

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Background: In people with cystic fibrosis infection with NonTuberculous Mycobacteria is of increasing prevalence. Mycobacterium abscessus complex is of particular concern and has been associated with adverse clinical outcomes. Optimal treatment usually requires multiple antibiotics for over 12 months. When considering lung transplantation for patients with NonTuberculous Mycobacteria potential benefits must be balanced against the risks of uncontrolled infection post-transplant and significant side-effects associated with treatment. In this survey we assessed current international practice with regard to assessing and listing patients for lung transplantation. Methods: We designed a questionnaire enquiring about local practice regarding screening for NonTuberculous Mycobacteria infection, specific contra-indications to transplantation, management and segregation of patients pre-and post-transplant. The survey was sent via e-mail to 37 paediatric and adult lung transplant centres across Europe, North America and Australia.

show abstract

Nontuberculous Mycobacteria in Cystic Fibrosis

Cited by 68 publications

References 84 publications

Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

Pulmonary disease by non-tuberculous mycobacteria – clinical management, unmet needs and future perspectives

NonTuberculous Mycobacteria Infection and Lung Transplantation in Cystic Fibrosis: A Worldwide Survey of Clinical Practice

Contact Info

Product

Resources

About